The Comprehensive Cancer Center of Metropolitan Detroit (CCCMD) received its initial core funding and designation by the Director of the National Cancer Institute in 1978. The CCCMD was established through the affiliation of the Michigan Cancer Foundation and the Wayne State University School of Medicine, for the purpose of facilitating interdisciplinary and interdepartmental activities in cancer research or education and cancer care, to coordinate and integrate the cancer-related activities in its metropolitan region, and of supporting the augmentation of cancer resources in this area. Since formation of the CCCMD, emphasis has been placed on the initiation and support of multi-disciplinary, interinstitutional, and broad-based projects and programs. The CCCMC core grant has provided the opportunity for the orderly acquisition of cancer research and resource facilities; superior staff development; establishment and sustenance of interinstitutional and interdepartmental cancer research collaborations; and overall enhancement of cancer research education and care achievements in Detroit. The task of coordinating the collaborative and multi-disciplinary programs described in this application falls to the leadership of the Center, the Director, the Deputy Director, and the Program Directors. Each Program Director is responsible for the planning and initiation of broad-based programs; and the Center's Operating Committee, which includes the Center Director, Deputy Director and Program Directors are responsible for overall program planning, cross-disciplinary collaborations, and the identification of worthwhile development projects in all areas. Core facility Directors are responsible for ensuring the availability of shared resources as quality control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-15
Application #
3101671
Study Section
Special Emphasis Panel (SRC (Q2))
Project Start
1988-04-01
Project End
1996-03-31
Budget Start
1992-05-01
Budget End
1993-03-31
Support Year
15
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
Schools of Medicine
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58
Vaishampayan, Ulka (2018) Advantages and Adversities of the Weighted Toxicity Score. Clin Cancer Res 24:4918-4920
Wang, Zhaoxian; Sau, Samaresh; Alsaab, Hashem O et al. (2018) CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 14:1441-1454
Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248
Kim, Seongho; Wong, Weng Kee (2018) Extended two-stage adaptive designs with three target responses for phase II clinical trials. Stat Methods Med Res 27:3628-3642

Showing the most recent 10 out of 826 publications